Over 200,000 patients are diagnosed with a rare cancer each year in the U.S. alone and these patients have little hope of a positive outcome. The British Journal of Cancer article “Rare Cancers: the greatest inequality in cancer research and oncology treatment” emphasizes there is a strong need in the area of rare cancers to start collecting meaningful genomics information to inform better science in the future for therapeutic interventions.
Jed Taxel died 6 months after his initial diagnosis. The 5-year survival rate for rare cancer patients like Jed is much lower than for patients diagnosed with common cancers, and results in a disproportionate number of all cancer deaths.
The diagnosis and treatment of rare cancers is challenging and oncologists who manage these patients find it difficult to access bona fide experts with meaningful treatment input. A major roadblock in identifying, developing, and evaluating therapies including precision medicine and immunotherapies for rare cancer is that only limited samples are available.
When looking at overall National Cancer Institute (NCI) funding allocations in cancer research, a comparison of spending on cancer research reveals discrepancies in the distribution of research funding, which is primarily focused on “common cancer” forms and fails to sufficiently fund rare cancer research.
That is the mission of the JEDI Rare Cancer Foundation. Innovative science is the only way rare cancer detection and treatment will improve. The foundation’s philanthropy is laser focused to advocate for and empower investigators, physicians, and cancer research institutions’ rare cancer efforts.
By fueling breakthroughs in rare cancer, the JEDI community continues to save lives around the world. Your generous donations support crucial rare cancer research and collaboration resulting in scientific breakthroughs, innovative clinical trials and improved treatments that change lives and enable better outcomes for rare cancer patients and their families.
Your generous donation is an investment in ending rare cancer as we know it.
We accelerate discovery
Comment, Like, Share & Follow Us on Social Media.
Together, we can take action against rare cancer and help save lives.
The Jed Ian Taxel Foundation for Rare Cancer Research | P.O. Box 683501 Park City, Utah 84068
The Jed Ian Taxel Foundation for Rare Cancer Research, Inc. is a 501 (C)(3) Non-Profit Organization, accepting Tax Deductible donations from individuals, corporations, family-advised funds and foundations. Federal Tax ID 86-2610819
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.